CITIC Securities: Maintains a "buy" rating on China National Pharmaceutical Group (01099.HK) as its third quarter performance meets previous expectations.

According to the Wise Finance APP, CITIC Securities released a research report stating that it is estimated that China National Pharmaceutical Group Corporation (01099.HK) will achieve operating revenues of 589.21 billion yuan, 619.91 billion yuan, and 651.89 billion yuan in 2025-2027, with year-on-year growth of 0.8%, 5.2%, and 5.2% respectively. It is expected to achieve a net profit attributable to the parent company of 7.266 billion yuan, 7.766 billion yuan, and 8.313 billion yuan, with year-on-year growth of 3.1%, 6.9%, and 7.0% respectively. The corresponding EPS will be 2.33 yuan/share, 2.49 yuan/share, and 2.66 yuan/share, with corresponding PE ratios of 7.8X, 7.3X, and 6.8X, maintaining a "buy" rating.